NuVasive Announces First Quarter 2018 Financial Results

Go back to NuVasive Announces First Quarter 2018 Financial Results

NuVasive (NUVA) PT Lowered to $65 at RBC Capital; 'Profitability Below Expectations'

May 2, 2018 8:37 AM EDT

RBC Capital lowered its price target on NuVasive (NASDAQ: NUVA) to $65.00 (from $70.00) while maintaining a Sector Perform rating.

Analyst Glenn Novarro commented, "NUVA's revenue growth should re-accelerate throughout 2018 as new product launches gain traction. Additionally, NUVA will debut its surgical intelligence... More

NuVasive (NUVA) Misses Q1 EPS by 6c; Reiterates Outlook

May 1, 2018 4:05 PM EDT

NuVasive (NASDAQ: NUVA) reported Q1 EPS of $0.39, $0.06 worse than the analyst estimate of $0.45. Revenue for the quarter came in at $260.5 million versus the consensus estimate of $259.43 million.

The Company reiterated its full-year 2018 guidance, and assumes a full-year benefit of U.S. tax... More